Recent reports in several medical journals, including JAMA, and the general media have highlighted the emergence of coronavirus disease 2019 (COVID-19)–associated inflammatory syndromes in children.1- 3 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to induce this new condition, which has been called pediatric multisystem inflammatory syndrome (PIMS) or pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS) and described in detail by investigators in Europe and New York, New York.1- 4 Additionally, investigators in Italy have reported5 a dramatic surge in Kawasaki disease (KD), often associated with positive serological test results for COVID-19. As of May 31, 2020, the New York State Department of Health is investigating 188 reported hospitalized cases and 3 deaths of children, predominantly school-aged, who experienced symptoms similar to KD and toxic shock–like syndrome that were possibly linked to COVID-19.6 Similarly, more than 200 cases have been reported to the European Centre for Disease Prevention and Control. The US Centers for Disease Control and Prevention has also issued a statement and case reports for the emerging condition, now also termed multisystem inflammatory syndrome of childhood (MIS-C), which is currently under investigation.7 Simultaneously, sporadic cases of MIS-C, KD, and/or Kawasaki shock syndrome have appeared in public health reports and the media, particularly in Washington and other West Coast states.